X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (625) 625
humans (567) 567
oncology (543) 543
mutation (496) 496
gefitinib (474) 474
acquired-resistance (453) 453
t790m (403) 403
t790m mutation (368) 368
lung neoplasms - drug therapy (362) 362
lung cancer (335) 335
lung neoplasms - genetics (324) 324
carcinoma, non-small-cell lung - drug therapy (296) 296
erlotinib (287) 287
chemotherapy (259) 259
cell lung-cancer (257) 257
epidermal growth factor (257) 257
receptor, epidermal growth factor - genetics (256) 256
egfr (253) 253
carcinoma, non-small-cell lung - genetics (251) 251
female (240) 240
tyrosine kinase inhibitors (239) 239
lung cancer, non-small cell (236) 236
open-label (224) 224
non-small cell lung cancer (220) 220
protein kinase inhibitors - therapeutic use (219) 219
respiratory tract diseases (214) 214
receptor, epidermal growth factor - antagonists & inhibitors (212) 212
male (206) 206
cancer (200) 200
lung neoplasms - pathology (191) 191
resistance (185) 185
1st-line treatment (184) 184
protein kinase inhibitors - pharmacology (178) 178
middle aged (176) 176
growth-factor receptor (171) 171
osimertinib (170) 170
antineoplastic agents - therapeutic use (168) 168
aged (167) 167
nsclc (165) 165
tyrosine (163) 163
adenocarcinoma (162) 162
genetic aspects (162) 162
epidermal growth factor receptor (160) 160
respiratory system (156) 156
carcinoma, non-small-cell lung - pathology (151) 151
cell line, tumor (148) 148
drug resistance, neoplasm - genetics (146) 146
erbb receptors - genetics (138) 138
animals (135) 135
azd9291 (134) 134
growth-factor-receptor (128) 128
kinases (128) 128
afatinib (126) 126
care and treatment (126) 126
drug resistance, neoplasm (126) 126
egfr mutation (124) 124
antineoplastic agents - pharmacology (122) 122
drug resistance (122) 122
tumors (120) 120
adult (114) 114
t790m mutations (114) 114
tyrosine kinase inhibitor (112) 112
analysis (110) 110
epidermal growth factor receptors (101) 101
aged, 80 and over (98) 98
acquired resistance (97) 97
mutations (96) 96
cancer therapies (95) 95
drug-resistance (93) 93
patients (93) 93
biopsy (92) 92
therapy (91) 91
non-small cell lung carcinoma (90) 90
health aspects (87) 87
research (85) 85
receptor, epidermal growth factor - metabolism (82) 82
treatment outcome (82) 82
development and progression (80) 80
quinazolines - therapeutic use (79) 79
egfr t790m (78) 78
cell biology (77) 77
chemistry, medicinal (76) 76
gene mutations (76) 76
kinase inhibitors (76) 76
biochemistry & molecular biology (75) 75
inhibitors (75) 75
lung neoplasms - metabolism (75) 75
egfr mutations (74) 74
quinazolines - pharmacology (72) 72
deoxyribonucleic acid--dna (71) 71
prognosis (71) 71
met amplification (70) 70
metastasis (70) 70
mice (69) 69
pharmacology & pharmacy (69) 69
erlotinib hydrochloride (68) 68
gefitinib resistance (68) 68
mutation - genetics (67) 67
article (65) 65
circulating tumor dna (65) 65
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1053) 1053
Chinese (16) 16
French (12) 12
Japanese (4) 4
German (2) 2
Polish (2) 2
Spanish (2) 2
Czech (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Life Sciences, ISSN 0024-3205, 10/2017, Volume 186, pp. 25 - 32
Clinical reports suggest that EGFR-mutated lung cancer usually respond significantly towards small molecule tyrosine kinase inhibitors. Same studies also... 
TOPK | T790M | ZEB1 | C797S | EGFR
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 12/2018, Volume 13, Issue 12, pp. e252 - e254
Journal Article
by Zhao, BB and Xiao, Z and Qi, JG and Luo, R and Lan, Z and Zhang, YZ and Hu, XH and Tang, QD and Zheng, PW and Xu, S and Zhu, WF
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0223-5234, 02/2019, Volume 163, pp. 367 - 380
Third-generation epidermal growth factor receptor (EGFR)(L858R.T790M) inhibitors are still the main drugs for the treatment of advanced non-small cell lung... 
1ST-LINE TREATMENT | GEFITINIB | CHEMISTRY, MEDICINAL | Selectivity | T790M | Epidermal growth factor receptor | T790M-MEDIATED RESISTANCE | CHEMOTHERAPY | DISCOVERY | L858R/T790M resistance mutation | CELL LUNG-CANCER | EGFR INHIBITORS | Non-small cell lung cancer | MUTATION | FLUORINE
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2018, Volume 29, Issue suppl_1, pp. i10 - i19
Journal Article
Journal Article
Cancer Discovery, ISSN 2159-8274, 12/2013, Volume 3, Issue 12, pp. 1404 - 1415
Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine... 
CELL LUNG-CANCER | MET AMPLIFICATION | ONCOLOGY | FACTOR RECEPTOR MUTATIONS | ACQUIRED-RESISTANCE | TYROSINE KINASE INHIBITOR | T790M MUTATION | OPEN-LABEL | AKT INHIBITOR | GEFITINIB RESISTANCE | AXL KINASE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Drug Resistance, Neoplasm | Epithelial-Mesenchymal Transition - drug effects | Lung Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Receptor, Epidermal Growth Factor - metabolism | HEK293 Cells | Female | Antineoplastic Agents - pharmacology | Acrylamides - pharmacology | Mutant Proteins - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Mice, Transgenic | Mutant Proteins - metabolism | Pyrimidines - pharmacology | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Acrylamides - administration & dosage | Mice, Nude | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug Screening Assays, Antitumor | T790M | drug resistance | NSCLC | EMT | EGFR
Journal Article
Current Oncology, ISSN 1198-0052, 06/2018, Volume 25, pp. S28 - S37
Journal Article
Oncotarget, ISSN 1949-2553, 10/2018, Volume 9, Issue 78, pp. 34765 - 34771
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are markedly effective for T790M-positive patients. To confer their... 
Osimertinib | T790M | Afatinib | Rebiopsy | Bevacizumab
Journal Article
NANO LETTERS, ISSN 1530-6984, 12/2017, Volume 17, Issue 12, pp. 7684 - 7690
Gefitinib is a first-line therapy in the EGFR-mutated nonsmall cell lung cancer (NSCLC). However, the development of drug resistance is almost unavoidable,... 
PHYSICS, CONDENSED MATTER | PHYSICS, APPLIED | vorinostat | nonsmall cell lung cancer | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | T790M MUTATION | NANOSCIENCE & NANOTECHNOLOGY | gefitinib | DRUG-RESISTANCE | CHEMISTRY, MULTIDISCIPLINARY | Tumor-associated macrophages | CELL LUNG-CANCER | EGFR(T790M) | drug resistance
Journal Article
Cancer Discovery, ISSN 2159-8274, 10/2012, Volume 2, Issue 10, pp. 922 - 933
EGFR-mutant lung cancers eventually become resistant to treatment with EGFR tyrosine kinase inhibitors (TKIs). The combination of EGFR-TKI afatinib and... 
lung cancer | EGFR tyrosine kinase inhibitors | afatinib | EGFR mutations | erlotinib | HER2 amplification | cetuximab | EGFR T790M | acquired resistance
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 17, pp. 13652 - 13665
Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using... 
X-ray crystallography | T790M/C797S | Structure-based drug design | Drug resistance | Lung cancer
Journal Article
Onkologie (Czech Republic), ISSN 1802-4475, 2017, Volume 11, Issue 2, pp. 72 - 77
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 10/2011, Volume 6, Issue 10, pp. 1639 - 1648
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1532 - 1539
Background: The efficacy of programmed death-1 blockade in epidermal growth factor receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC)... 
PD-L1 | tumor-infiltrating lymphocyte | T790M | nivolumab | epidermal growth factor receptor | non-small-cell lung cancer | ONCOLOGY | PD-L1 EXPRESSION | BLOCKADE
Journal Article